Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Baxter GMP Warning Letter Driven By Rainbow Of Tablet Colors

This article was originally published in The Pink Sheet Daily

Executive Summary

Baxter HealthCare's Puerto Rico manufacturing facilities were turning out such quantities of discolored drugs the company produced a color chart telling end users when to discard them.

You may also be interested in...



GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant

Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.

GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant

Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.

GMP Closeout "Carrots" Sprout; Baxter Receives First, But FDA Is Subdued

If the first-ever FDA closeout letter to an Rx manufacturer is any indication, the correspondence may not offer a clear-cut end to compliance issues cited in warning letters

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel